Clinical characteristics of patients (N = 156)
| Characteristic . | No. . | % . |
|---|---|---|
| Age, y | ||
| Median | 56 | |
| Range | 34-73 | |
| Male sex | 89 | 57 |
| IgH | ||
| IgG | 81 | 52 |
| IgA | 36 | 23 |
| IgD | 2 | 1 |
| No heavy chain | 22 | 14 |
| No data | 15 | 10 |
| IgL | ||
| κ | 94 | 60 |
| Λ | 41 | 26 |
| No data | 21 | 14 |
| ISS score | ||
| I | 63 | 40 |
| II | 56 | 36 |
| III | 33 | 21 |
| No data | 4 | 3 |
| FISH* | ||
| del(13q) | 59 | 40 |
| t(4;14) | 14 | 10 |
| del(17p) | 5 | 3 |
| High risk† | 17 | 12 |
| PFS | ||
| Relapse or death | 111 | 71 |
| 3 years | 50 | |
| 95% CI | 42-28 | |
| OS | ||
| Death | 27 | 17 |
| 3 years | 97 | |
| 95% CI | 95-99 | |
| Follow-up, years | ||
| Median | 5.6 | |
| IQR | 5.4-5.9 | |
| Characteristic . | No. . | % . |
|---|---|---|
| Age, y | ||
| Median | 56 | |
| Range | 34-73 | |
| Male sex | 89 | 57 |
| IgH | ||
| IgG | 81 | 52 |
| IgA | 36 | 23 |
| IgD | 2 | 1 |
| No heavy chain | 22 | 14 |
| No data | 15 | 10 |
| IgL | ||
| κ | 94 | 60 |
| Λ | 41 | 26 |
| No data | 21 | 14 |
| ISS score | ||
| I | 63 | 40 |
| II | 56 | 36 |
| III | 33 | 21 |
| No data | 4 | 3 |
| FISH* | ||
| del(13q) | 59 | 40 |
| t(4;14) | 14 | 10 |
| del(17p) | 5 | 3 |
| High risk† | 17 | 12 |
| PFS | ||
| Relapse or death | 111 | 71 |
| 3 years | 50 | |
| 95% CI | 42-28 | |
| OS | ||
| Death | 27 | 17 |
| 3 years | 97 | |
| 95% CI | 95-99 | |
| Follow-up, years | ||
| Median | 5.6 | |
| IQR | 5.4-5.9 | |
CI, confidence interval; FISH, fluorescence in situ hybridization; IgH, immunoglobulin heavy chain; IgL, immunoglobulin light chain; IQR, interquartile range.
del(13q): unknown for 7 participants; t(4;14): unknown for 13 participants; del(17p): unknown for 8 participants.
High-risk cytogenetics include t(4;14) and/or del(17p).